[go: up one dir, main page]

CA2335876A1 - Inhibiteurs de proteases - Google Patents

Inhibiteurs de proteases Download PDF

Info

Publication number
CA2335876A1
CA2335876A1 CA002335876A CA2335876A CA2335876A1 CA 2335876 A1 CA2335876 A1 CA 2335876A1 CA 002335876 A CA002335876 A CA 002335876A CA 2335876 A CA2335876 A CA 2335876A CA 2335876 A1 CA2335876 A1 CA 2335876A1
Authority
CA
Canada
Prior art keywords
ylcarbonyl
thiazol
hydrazide
methylpropyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002335876A
Other languages
English (en)
Inventor
Evelyne Michaud
Stacie Marie Halbert
Scott Kevin Thompson
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2335876A1 publication Critical patent/CA2335876A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention porte sur des composés de diacylhydrazine et leurs sels, hydrates et solvates pharmacocompatibles inhibant les protéases, y compris la cathépsine K, sur des préparations pharmaceutiques contenant ces composés, sur de nouveaux intermédiaires de ces composés, sur des procédés de traitement des pertes osseuses excessives, ou la dégradation des matrices ou cartilages dont l'ostéoporose, les maladies gingivales dont la gingivite et la périodontite, l'arthrite et plus spécialement l'ostéoarthrite et l'arthrite chronique, la maladie de Piaget, l'hypercalcémie maligne, les troubles du métabolisme de l'os, consistant à inhiber lesdites pertes osseuses excessives, ou la dégradation des matrices ou cartilages par administration à un patient le nécessitant un des composés de la présente invention.
CA002335876A 1998-06-24 1999-06-24 Inhibiteurs de proteases Abandoned CA2335876A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9049398P 1998-06-24 1998-06-24
US60/090,493 1998-06-24
PCT/US1999/014561 WO1999066925A1 (fr) 1998-06-24 1999-06-24 Inhibiteurs de proteases

Publications (1)

Publication Number Publication Date
CA2335876A1 true CA2335876A1 (fr) 1999-12-29

Family

ID=22223011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335876A Abandoned CA2335876A1 (fr) 1998-06-24 1999-06-24 Inhibiteurs de proteases

Country Status (6)

Country Link
EP (1) EP1093367A4 (fr)
JP (1) JP2002518444A (fr)
AR (1) AR018915A1 (fr)
AU (1) AU4723799A (fr)
CA (1) CA2335876A1 (fr)
WO (1) WO1999066925A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1232154A4 (fr) 1999-11-10 2004-06-23 Smithkline Beecham Corp Inhibiteurs de protease
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
AU4344101A (en) 2000-03-21 2001-10-03 Smithkline Beecham Corp Protease inhibitors
EP1465862A1 (fr) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Derives de cetoamides a substitution cycloalkyle, utiles comme inhibiteurs de cathepsine k
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
AU2004289305A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-Hydrazone compounds
PT2439205E (pt) * 2006-12-29 2015-07-16 Abbvie Deutschland Compostos de carboxamida e seus usos como inibidores de calpaína
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
CN102408387A (zh) * 2010-09-26 2012-04-11 韩南银 一种具有抗肿瘤作用的金属络合物
JP6243908B2 (ja) * 2012-08-23 2017-12-06 アリオス バイオファーマ インク． パラミクソウイルス感染症を治療するための化合物
CN103113300A (zh) * 2013-03-06 2013-05-22 广西中医药大学 一种具有抗肿瘤活性的化合物的制备方法和用途
WO2014179943A1 (fr) * 2013-05-08 2014-11-13 Yang Yongliang Composé amide maléique, son procédé de préparation et application associée
CN103242321A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 苄基哌嗪类化合物及其抗肿瘤用途
HK1225716A1 (zh) 2013-08-21 2017-09-15 Alios Biopharma, Inc. 抗病毒化合物
CN103880702B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗白血病药物中的应用
CN103880701B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗人宫颈鳞状癌药物中的应用
CN103880703B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗人胎盘绒毛癌药物中的应用
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use

Also Published As

Publication number Publication date
EP1093367A4 (fr) 2003-03-05
AU4723799A (en) 2000-01-10
WO1999066925A1 (fr) 1999-12-29
EP1093367A1 (fr) 2001-04-25
JP2002518444A (ja) 2002-06-25
AR018915A1 (es) 2001-12-12

Similar Documents

Publication Publication Date Title
CA2335876A1 (fr) Inhibiteurs de proteases
US6369077B1 (en) Protease inhibitors
US6331542B1 (en) Protease inhibitors
WO1998048799A1 (fr) Inhibiteurs de proteases
AU734302B2 (en) Protease inhibitors
CA2327282A1 (fr) Traitement de maladies parasitaires par l'inhibition des cysteine-proteases de la superfamille de la papaine
US6518267B1 (en) Protease inhibitors
WO1998008802A1 (fr) Inhibiteurs de cysteine protease
CA2287567A1 (fr) Inhibiteurs de proteases
CA2332492A1 (fr) Inhibiteurs de la protease
US20020049316A1 (en) Protease inhibitors
EP1153022A1 (fr) Inhibiteurs de protease
JP2001514257A (ja) プロテアーゼ阻害剤
JP2002533452A (ja) プロテアーゼ阻害剤
JP2002540199A (ja) プロテアーゼ阻害剤
CA2285601A1 (fr) Inhibiteurs de proteases
US20020173469A1 (en) Protease inhibitors
US20020165222A1 (en) Protease inhibitors
CZ393499A3 (cs) Inhibitory proteasy
CZ380999A3 (cs) Inhibitory proteáz
MXPA99009976A (en) Protease inhibitors
AU2260400A (en) Protease inhibitors - IV
AU2260500A (en) Protease inhibitors - III
AU2260300A (en) Protease inhibitors - II

Legal Events

Date Code Title Description
FZDE Dead